OrphanPulse Wk 29: Ionis Takes SMA-Proven Antisense Into Dravet Syndrome
A week defined by first-in-human starts across rare genetic disease, led by antisense entering Dravet syndrome from the field that already rewrote the SMA story. Around it, first patients dosed in rare vascular and cardiomyopathy programs with near-empty competitive fields, a first-in-class readout in HIT, and orphan designations that quietly reshape the economics behind them.
developments
in human
designations
eligible
in class
Ionis puts antisense into Dravet syndrome, and the modality that rewrote SMA takes on genetic pediatric epilepsy
The lead this week is a starting gun, and the honest framing is exactly that: first patient dosed, years from proof. Ionis began its Phase 1/2 ASCEND study of ION337, an antisense oligonucleotide, in Dravet syndrome, a severe genetic epilepsy that begins in infancy and has no disease-modifying therapy. What makes it the lead is the combination of who, what and where. Who: Ionis is the acknowledged pioneer of antisense chemistry. What: antisense is the modality that already transformed spinal muscular atrophy from a fatal diagnosis into a treatable one, so applying it to another defined genetic pediatric disease is a credible bet, not a speculative one. Where: Dravet is a well-characterised, single-gene condition with a fiercely engaged advocacy community, which is both a clinical advantage (clear patient identification) and a distribution one (rare pediatric first-in-human news travels through networks that amplify hard). Log it as a low-confidence early asset with an unusually strong pedigree behind it.
Diagonal doses the first patient in a Phase 1/2 trial of DIAG723 for hereditary hemorrhagic telangiectasia
Diagonal Therapeutics began dosing DIAG723, an antibody, in a Phase 1/2 trial for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disorder with no approved disease-modifying treatment. HHT is exactly the kind of defined, under-served rare indication where a first credible mechanism can define the category and the eventual pricing power. Early-stage, so this is a shot on goal rather than a result, but a first-in-class antibody entering the clinic in a disease that has had none is a genuine marker. The competitive field here is close to empty, which is the point.
Atrium clears an FDA IND for ATR-1072 in PRKAG2 syndrome, an ultra-rare genetic cardiomyopathy
Atrium Therapeutics received FDA clearance of its IND for ATR-1072 (an RNA-targeting candidate) in PRKAG2 syndrome, an ultra-rare inherited cardiomyopathy. This is as early as it gets and should be marked accordingly, but ultra-rare genetic cardiomyopathies are a frontier where RNA and gene-directed approaches are opening doors that were shut. An IND clearance is permission to begin; the value here is optionality in a single-gene disease with a clearly identifiable patient population and no competition to speak of.
Cadrenal’s CAD-1005 cuts thrombotic events over 25 percent in HIT in late-breaking Phase 2 data
Cadrenal reported late-breaking Phase 2 data at ISTH 2026 showing its first-in-class 12-LOX inhibitor CAD-1005 reduced thrombotic events by more than 25 percent in heparin-induced thrombocytopenia (HIT). Unlike the earlier-stage entries this week, this is actual efficacy data in patients, and in a serious, acute condition with limited targeted options. A first-in-class mechanism posting a clear event reduction is the profile that attracts both partners and accelerated regulatory interest. This is the item on the board with the most mature evidence behind it.
Niagen wins US Rare Pediatric Disease and EMA orphan designations for NB4168 in ataxia-telangiectasia
Niagen Bioscience secured FDA Rare Pediatric Disease designation and EMA orphan status for NB4168 in ataxia-telangiectasia, a rare inherited neurodegenerative disease of childhood. The dual-designation detail is the commercially meaningful part: RPD designation carries eligibility for a priority review voucher, an asset with real transferable value, and orphan status brings the market-exclusivity and incentive package on both sides of the Atlantic. For a rare-disease developer, this is the regulatory scaffolding that makes an ultra-rare pediatric program financeable. Log the PRV eligibility specifically, it is the kind of detail that changes a program’s economics.
Vanda gets an EMA positive opinion for orphan designation of imsidolimab in generalized pustular psoriasis
Vanda Pharmaceuticals received an EMA positive opinion for orphan drug designation of imsidolimab in generalized pustular psoriasis (GPP). Beyond the asset itself, the notable point is Europe formally recognising GPP as a distinct rare disease, a classification move that shapes the reimbursement and access path for everything that follows in the indication. Orphan designation secures the incentive framework; the disease-definition recognition is the quieter structural win that benefits the whole category. This is a regulatory-and-access story as much as a product one.
Servier completes its acquisition of Edgewise’s muscular dystrophy business
Servier closed its purchase of Edgewise Therapeutics’ muscular dystrophy assets. Muscular dystrophy sits squarely in the rare-neuromuscular space, and the read is that Servier is buying committed, later-shaped programs to build depth in a defined rare lane rather than betting on discovery. This is the recurring rare-disease acquisition logic in action: durable orphan pricing against clearly identified, highly motivated patient populations keeps drawing acquirers toward assets that are already de-risked on biology. A directional signal about where a mid-cap sees defensible value.
When a rare-disease move gets big enough, it earns a full report.
Synopulse’s monthly intelligence line: deep, single-subject reports on the moves that reshape a field.